Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5183-5190

  Li, Xiaolin ^a   Xu, Hua'e ^a   Dai, Xinzheng ^a,b   Zhu, Zhenshu ^c   Liu, Baorui ^d   Lu, Xiaowei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

^d MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Liver cancer; Nanoparticle; Paclitaxel; Tetrandrine

Indexed keywords

ANTINEOPLASTIC AGENT; COPOLYMER; NANOPARTICLE; PACLITAXEL PLUS TETRANDRINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADABILITY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG STABILITY; IN VIVO STUDY; LIVER CANCER; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; OVERALL SURVIVAL; PARTICLE SIZE; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZYLISOQUINOLINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DRUG SYNERGISM; MICE; NANOCAPSULES; PACLITAXEL; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

MUS;

EID: 84870352614     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S34886     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. American Cancer Society. Cancer Facts and Figures 2012. Atlanta, GA: American Cancer Society; 2012.
3. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry. 1993;32(11):2747-2755.
4. Strumberg D, Erhard J, Harstrick A, etal. Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma. Eur J Cancer. 1998;34(8):1290-1292.
5. Chao Y, Chan WK, Birkhofer MJ, etal. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer. 1998;78(1):34-39.
6. Dorr RT. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother. 1994;28(Suppl 5):S11-S14.
7. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs. 1995;6(3):339-355.
8. Kang HS, Kim YH, Lee CS, Lee JJ, Choi I, Pyun KH. Anti-inflammatory effects of Stephania tetrandra S. Moore on interleukin-6 production and experimental inflammatory disease models. Mediators Inflamm. 1996;5(4):280-291.
9. Meng LH, Zhang H, Hayward L, Takemura H, Shao RG, Pommier Y. Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1. Cancer Res. 2004;64(24):9086-9092.
10. Wu JM, Chen Y, Chen JC, Lin TY, Tseng SH. Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice. Cancer Lett. 2010;287(2):187-195.
11. Oh SH, Lee BH. Induction of apoptosis in human hepatoblastoma cells by tetrandrine via caspase-dependent Bid cleavage and cytochrome c release. Biochem Pharmacol. 2003;66(5):725-731.
12. Fu LW, Zhang YM, Liang YJ, Yang XP, Pan QC. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur J Cancer. 2002;38(3):418-426.
13. Choi SU, Park SH, Kim KH, etal. The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anticancer Drugs. 1998;9(3):255-261.
14. Wei J, Liu B, Wang L, Qian X, Ding Y, Yu L. Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines. Cancer Chemother Pharmacol. 2007;60(5): 703-711.
15. Li X, Lu X, Xu H, etal. Paclitaxel/tetrandrine coloaded nanoparticles effectively promote the apoptosis of gastric cancer cells based on "oxidation therapy. " Mol Pharm. 2012;9(2):222-229.
16. Li X, Li R, Qian X, etal. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm. 2008;70(3):726-734.
17. Shao J, Zheng D, Jiang Z, etal. Curcumin delivery by methoxy polyethylene glycol-poly(caprolactone) nanoparticles inhibits the growth of C6glioma cells. Acta Biochim Biophys Sin (Shanghai). 2011;43(4):267-274.
18. Herold DA, Keil K, Bruns DE. Oxidation of polyethylene glycol by alcohol dehydrogenase. Biochem Pharmacol. 1989;38(1):73-76.
19. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41(2):189-207.
20. Idani H, Matsuoka J, Yasuda T, Kobayashi K, Tanaka N. Intra-tumoral injection of doxorubicin (Adriamycin) encapsulated in liposome inhibits tumor growth, prolongs survival time and is not associated with local or systemic side effects. Int J Cancer. 2000;88(4):645-651.
21. Li X, Zhen D, Lu X, etal. Enhanced cytotoxicity and activation of ROS-dependent c-Jun NH2-terminal kinase and caspase-3 by low doses of tetrandrine-loaded nanoparticles in Lovo cells-a possible Trojan strategy against cancer. Eur J Pharm Biopharm. 2010;75(3):334-340.
22. Ma X, Wang H, Jin S, Wu Y, Liang XJ. Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-g-poly (lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity. Int J Nanomedicine. 2012;7:1313-1328.
23. Wang J, Mongayt D, Torchilin VP. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target. 2005;13(1):73-80.
24. Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modified poly(β-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Mol Pharm. 2005;2(5):357-366.
25. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H. Intratumoral chemotherapy. Neurosurgery. 1995;37(6):1128-1145.